Multidrug-resistant tuberculosis in children: Are the same therapy options available worldwide?

Area of Science:

• Global Health
• Infectious Diseases
• Pediatric Medicine

Background:

• Drug-resistant tuberculosis (TB) poses a significant global health challenge, particularly for children.
• Existing treatment regimens for drug-resistant TB often lack child-friendly formulations, hindering adherence and treatment success.
• The reappraisal of older drugs and development of new medicines are ongoing efforts to combat resistant TB strains.

Purpose of the Study:

• To assess the global availability of child-friendly medicines for treating drug-resistant TB.
• To highlight the importance of pediatric formulations in managing drug-resistant TB in children.
• To advocate for increased efforts in developing and distributing pediatric TB treatments.

Main Methods:

• This perspective reviews the current landscape of child-friendly medicines for drug-resistant TB.
• It analyzes the need for improved formulations based on treatment duration and adherence challenges.
• The study emphasizes the global nature of pediatric drug-resistant TB as a medical problem.

Main Results:

• The availability of child-friendly formulations for drug-resistant TB treatment remains a significant global challenge.
• There is a critical need to encourage the development of such formulations to improve treatment adherence.
• Current strategies require enhanced efforts from pharmaceutical companies and policymakers.

Conclusions:

• Development of child-friendly formulations for second-line drugs is essential for treating drug-resistant TB in children.
• Improved adherence through appropriate formulations can increase treatment success rates and prevent further resistance.
• Urgent, concerted efforts are needed from companies and policymakers to ensure global availability of these vital pediatric medicines.